Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HPV vaccines--why aren't they the answer yet?

Amy Kirkpatrick Brown1, Richard G Moore

  • 1Program in Women's Oncology, Women & Infants' Hospital, Providence, RI 02905, USA. ABrown@WIHRI.org

Medicine and Health, Rhode Island
|May 27, 2005
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same author

Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9.

bioRxiv : the preprint server for biology·2026
Same author

Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.

Gynecologic oncology·2026
Same author

Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2.

bioRxiv : the preprint server for biology·2026
Same author

First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026